CymaBay Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$105,370,000 and profit margin reached -339%. Total operating expenses were $132,071,000.

Profit Margin

CymaBay Therapeutics, Inc. (NASDAQ:CBAY): Profit margin
2014 0 -31.91M
2015 0 -15.52M
2016 0 -26.67M
2017 10M -27.55M -275.57%
2018 0 -72.54M
2019 0 -102.23M
2020 0 -48.66M
2021 0 -92.58M
2022 0 -118.89M
2023 31.07M -105.37M -339.1%

CBAY Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
31.07M0000010M000
Cost of revenue
681K710K688K632K800K00000
Gross profit
30.39M-710K-688K-632K-800K010M000
Operating exp.
Research and development
80.11M67.99M64.54M35.88M83.83M58.12M18.93M15.94M17.02M15.82M
Selling and marketing
0000000000
Total operating expenses
132.07M93.11M87.58M53.30M103.07M72.50M31.32M25.58M25.89M24.00M
Operating income
-101.67M-93.11M-87.58M-52.60M-108.15M-72.50M-21.32M-25.58M-25.89M-24.00M
Other income (expenses), net
-3.69M-12.89M-2.41M1.61M5.34M-3.69M-6.23M76K10.36M-7.90M
Income before tax
-105.37M-106.00M-89.99M-50.98M-102.80M-72.54M-27.55M-26.67M-15.52M-31.91M
Income tax expense
012.89M2.58M-2.32M-572K293K-4.69M1.41M12.03M-6.47M
Net income
-105.37M-118.89M-92.58M-48.66M-102.23M-72.54M-27.55M-26.67M-15.52M-31.91M
Earnings per share
Basic EPS
-0.99-1.35-1.3-0.71-1.53-1.25-0.79-1.14-0.82-2.65
Diluted EPS
-0.99-1.35-1.3-0.71-1.53-1.25-0.79-1.14-0.82-2.65
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source